Forte Biosciences, Inc.
FBRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $39 | $9 | $0 | $36 |
| Gross Profit | -$39 | -$9 | $0 | -$36 |
| % Margin | – | – | – | – |
| R&D Expenses | $21,193 | $21,862 | $5,594 | $13,853 |
| G&A Expenses | $0 | $10,624 | $8,302 | $7,633 |
| SG&A Expenses | $15,370 | $10,615 | $8,302 | $7,633 |
| Sales & Mktg Exp. | $0 | -$9 | $0 | $0 |
| Other Operating Expenses | $0 | -$0 | $17 | $0 |
| Operating Expenses | $36,563 | $32,477 | $13,896 | $21,486 |
| Operating Income | -$36,602 | -$32,486 | -$13,896 | -$21,486 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1,124 | $1,010 | $17 | -$222 |
| Pre-Tax Income | -$35,478 | -$31,476 | -$13,879 | -$21,708 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$35,478 | -$31,476 | -$13,862 | -$21,708 |
| % Margin | – | – | – | – |
| EPS | -12.17 | -24.92 | -19.96 | -38.854 |
| % Growth | 51.2% | -24.8% | 48.6% | – |
| EPS Diluted | -12.17 | -24.92 | -19.96 | -38.854 |
| Weighted Avg Shares Out | 2,916 | 1,263 | 695 | 559 |
| Weighted Avg Shares Out Dil | 2,916 | 1,263 | 695 | 559 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,314 | $1,124 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $39 | $9 | $36 | $36 |
| EBITDA | -$35,439 | -$32,477 | -$13,860 | -$21,450 |
| % Margin | – | – | – | – |